Stock listing
VKTX Stock Price, News, Filings & Events — Viking Therapeutics, Inc.
Selected listing: VKTX · BX · CHF · CH
This page tracks Viking Therapeutics, Inc.'s VKTX:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following VKTX:BX. VKTX:BX is the stock-level entry point for investors researching Viking Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Viking Therapeutics, Inc. is a public company traded on the American market under the ticker VKTX. The company has a market capitalization of approximately $4.04 billion. Viking Therapeutics focuses on developing innovative therapies for metabolic and endocrine disorders.
- Ticker
- VKTX:BX
- Asset type
- Stock
- Market cap
- $3.75B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- BX
- Currency
- CHF
Viking Therapeutics, Inc. VKTX:BX stock context
This page tracks Viking Therapeutics, Inc.'s VKTX:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following VKTX:BX. VKTX:BX is the stock-level entry point for investors researching Viking Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Viking Therapeutics, Inc. is a public company traded on the American market under the ticker VKTX. The company has a market capitalization of approximately $4.04 billion. Viking Therapeutics focuses on developing innovative therapies for metabolic and endocrine disorders.
Latest news from Viking Therapeutics, Inc.
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
July 29, 2026
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
July 23, 2026
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
July 22, 2026
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
June 24, 2026
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
June 11, 2026
Viking Therapeutics, Inc. earnings calls
Viking Therapeutics, Inc. (0VQA) Q2 2026 Earnings Call
July 29, 2026 · Replay with transcript and chapters
Viking Therapeutics, Inc. (0VQA) Q1 2026 Earnings Call
April 29, 2026 · Replay with transcript and chapters
Viking Therapeutics, Inc. (0VQA) Q4 2025 Earnings Call
February 11, 2026 · Replay with transcript and chapters
Viking Therapeutics, Inc. (0VQA) Q3 2025 Earnings Call
October 22, 2025 · Replay with transcript and chapters
Viking Therapeutics, Inc. (0VQA) Q2 2025 Earnings Call
July 23, 2025 · Replay with transcript and chapters
Viking Therapeutics, Inc. (0VQA) Q1 2025 Earnings Call
April 23, 2025 · Replay with transcript and chapters
Research Viking Therapeutics, Inc.
Viking Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for VKTX:BX.
Viking Therapeutics, Inc. company profile
View the public company page for Viking Therapeutics, Inc. on 6ix.
Viking Therapeutics, Inc. news
Read company news and market updates connected to Viking Therapeutics, Inc..
Viking Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Viking Therapeutics, Inc..
Alternate listings
VKTX:NASDAQ
US · USD
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
1VT:GETTEX
DE · EUR
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
A12GD6:LSX
DE · EUR
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
1VT:TRADEGATE
DE · EUR
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
1VT:FWB
DE · EUR
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
A12GD6:LS
DE · EUR
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
1VKTX:MIL
IT · EUR
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
0VQA:LSE
GB · USD
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
VKTX:BOATS
US · USD
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
1VT:SWB
DE · EUR
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
1VT:DUS
DE · EUR
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.
1VT:HAM
DE · EUR
Alternate listing for Viking Therapeutics, Inc.; the primary context on this page is VKTX:BX.